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Common genetic variation could alter the risk for developing bladder cancer. We conducted a large-scale evaluation of
single nucleotide polymorphisms (SNPs) in candidate genes for cancer to identify common variants that influence
bladder cancer risk. An Illumina GoldenGate assay was used to genotype 1,433 SNPs within or near 386 genes in 1,086
cases and 1,033 controls in Spain. The most significant finding was in the 59 UTR of VEGF (rs25648, p for likelihood ratio
test, 2 degrees of freedom ¼ 1 3 10
 5). To further investigate the region, we analyzed 29 additional SNPs in VEGF,
selected to saturate the promoter and 59 UTR and to tag common genetic variation in this gene. Three additional SNPs
in the promoter region (rs833052, rs1109324, and rs1547651) were associated with increased risk for bladder cancer:
odds ratio (95% confidence interval): 2.52 (1.06–5.97), 2.74 (1.26–5.98), and 3.02 (1.36–6.63), respectively; and a
polymorphism in intron 2 (rs3024994) was associated with reduced risk: 0.65 (0.46–0.91). Two of the promoter SNPs
and the intron 2 SNP showed linkage disequilibrium with rs25648. Haplotype analyses revealed three blocks of linkage
disequilibrium with significant associations for two blocks including the promoter and 59 UTR (global p ¼ 0.02 and
0.009, respectively). These findings are biologically plausible since VEGF is critical in angiogenesis, which is important
for tumor growth, its elevated expression in bladder tumors correlates with tumor progression, and specific 59 UTR
haplotypes have been shown to influence promoter activity. Associations between bladder cancer risk and other genes
in this report were not robust based on false discovery rate calculations. In conclusion, this large-scale evaluation of
candidate cancer genes has identified common genetic variants in the regulatory regions of VEGF that could be
associated with bladder cancer risk.
Citation: Garcı ´a-Closas M, Malats N, Real FX, Yeager M, Welch R, et al. (2007) Large-scale evaluation of candidate genes for cancer identifies associations between VEGF
polymorphisms and bladder cancer risk. PLoS Genet 3(2): e29. doi:10.1371/journal.pgen.0030029
Introduction
Bladder cancer is primarily a sporadic disease, and
environmental factors such as tobacco smoking and occupa-
tional exposure to aromatic amines have been established as
strong determinants of risk [1]. A moderate familial compo-
nent has been demonstrated for bladder cancer, but so far no
high-penetrance mutations have been described [1]. However,
there is strong evidence for the inﬂuence of common genetic
variants on bladder cancer risk. Most notably, large studies
have demonstrated associations with each of the NAT2 and
GSTM1 genotypes and a probable interaction between
smoking and NAT2 genotype [2]. Speciﬁcally, the GSTM1
null genotype increases the overall risk of bladder cancer;
while the NAT2 slow acetylator genotype appears to increase
risk particularly among cigarette smokers [2]. In this context,
we hypothesized that a large-scale effort to screen common
variants in candidate cancer genes could identify additional
bladder cancer susceptibility genes.
The recent development of highly multiplexed single
nucleotide polymorphism (SNP) genotyping assays has re-
sulted in an opportunity to screen candidate genetic variants
in an affordable, high-throughput manner in epidemiological
studies. We used a GoldenGate assay by Illumina targeted to
analyze over 1,500 SNPs in selected candidate cancer genes in
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samples collected in a large case-control study of bladder
cancer in Spain. Because this was one of the ﬁrst epidemio-
logical studies using this highly multiplexed technology, we
performed a detailed analysis of data quality. All SNPs chosen
for this platform were drawn from the SNP500Cancer public
database (http://snp500cancer.nci.nih.gov), which includes
genes or speciﬁc genetic variants that could be important
in cancer and have been re-sequenced in 102 individuals [3].
Results
We obtained high-quality genotype calls from 1,433 SNP
assays in or near 386 genes involved in cancer-related
pathways, with a median of two SNPs per gene (range: 1–37
SNPs per gene). About half (51%) of these SNPs were located
in introns, 32% in exons, 12% in promoter regions, and 5%
in 39 of stop codon (STP). For SNPs located in exons, 5% were
in 59 UTRs, 68% in coding regions (approximately half were
synonymous and half non-synonymous changes) and 27% in
39 UTRs. The median (range) minor allele frequency (MAF)
among controls was 0.24 (0.02–0.50).
The global genotype completion for study samples was
 99%. Genotype concordance in 69 blinded duplicate blood
DNA pairs was  99%. Of the 1,433 SNPs in the GoldenGate
assay, 72 SNPs had been previously typed using other
genotyping platforms on 2,256 blood DNA samples from
study participants, and 31 of these SNPs had been previously
genotyped on 50 buccal DNA samples from the study.
Genotype concordance between the GoldenGate and other
platforms (primarily TaqMan) was  98%. About 5% (79/
1433) of genotype assays had a signiﬁcant (p , 0.05) departure
from Hardy-Weinberg equilibrium, which is consistent with
what would be expected by chance.
Gene-based (Table 1) and SNP-based (Table S1) analyses
showed promising associations (i.e., p-value for trend or
likelihood ratio test [LRT]; 2 degrees of freedom [df] ,0.01)
with bladder cancer risk for 19 genes: VEGF, STK11, CYP1B1,
ZNF350, PTH, GHR, CASP9, PLA2G6, GSTA4, ROS1, RB1CC1,
TERT, XRCC4, FZD7, CETP, CYP24A1, LIPC, ESR1, and
HSD17B4. In addition, ARHGDIB, SHBG, GPX4, and STAT1
showed signiﬁcant associations with risk according to the
LRT (2 df); however, estimates for heterozygous and
homozygous variants showed associations in opposite direc-
tions (Table S2).
The most signiﬁcant association with bladder cancer risk
according to gene-based analyses was observed for the
vascular endothelial growth factor (VEGF) gene (Table 1).
We evaluated these ﬁndings using the false discovery rate
(FDR) approach described in Materials and Methods. FDR
values for the VEGF association with bladder cancer risk,
taking into account all 386 genes evaluated in this report, was
0.032 based on the global p- v a l u e sf r o mL R T s( 2d f )
Table 1. Global Gene p-values for Significant (p-value   0.01) Associations between Bladder Cancer and Common Genetic Variation in
Selected Candidate Genes among the 1,086 Cases and 1,033 Controls in the Spanish Bladder Cancer Study
Gene
Symbol
Number of SNPs
a
per Gene
Global p-value
b
for Genotype Associations
Global p-value
c Based on
Trend Test for Individual SNPs
VEGF 3 0.00008 0.015
STK11 1 0.003 0.259
CYP1B1 8 0.007 0.017
ARHGDIB 2 0.010 0.861
ZNF350 1 0.012 0.010
STAT1 1 0.013 0.942
PTH 3 0.025 0.004
GHR 17 0.050 0.001
CASP9 3 0.044 0.012
PLA2G6 3 0.047 0.013
RB1CC1 3 0.083 0.014
GSTA4 4 0.113 0.016
ROS1 4 0.119 0.015
VEGF: Vascular endothelial growth factor; STK11: Serine/threonine kinase 11; CYP1B1: Cytochrome P450, family 1, subfamily B, polypeptide 1; ARHGDIB: Rho GDP dissociation inhibitor (GDI)
beta; ZNF350: Zinc finger protein 350; STAT1: Signal transducer and activator of transcription 1, 91kDa; PTH: Parathyroid hormone receptor 1; GHR: Growth hormone receptor; CASP9:
Caspase 9, apoptosis-related cysteine peptidase; PLA2G6: phospholipase A2, group VI ; RB1CC1: RB1-inducible coiled-coil 1; GSTA4: glutathione S-transferase A4; ROS1: v-ros UR2 sarcoma
virus oncogene homolog 1 (avian).
aSee Table S1 for details on SNPs included in each model.
bLRT with df ¼ number of SNPs per gene included in the model 3 2.
cLRT with df ¼ number of SNPs per gene included in the model.
doi:10.1371/journal.pgen.0030029.t001
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Author Summary
This article reports findings from a large-scale evaluation of common
variation in candidate genes for cancer to identify variants that
influence bladder cancer risk. We first evaluated 1,433 common
variants within or near 386 genes in a large case-control study in
Spain. The most significant finding was the gene coding for the
vascular endothelial growth factor (VEGF). To further investigate this
finding, we identified markers that captured most common variation
in the whole gene. Analyses indicated that variants in regulatory
regions of VEGF could modify the risk for developing bladder cancer.
This association is biologically plausible since VEGF is critical for the
growth of new blood vessels, which is important for tumor
development, and its elevated expression in bladder tumors
correlates with tumor progression. Future studies are required to
confirm these findings, as well as to investigate the mechanisms for
the observed associations.performed for each gene. The next lowest FDR value was 0.56
for STK11, indicating that the associations for other genes
were not robust. We also calculated FDR values for the 386
trend tests performed for each gene, and the lowest FDR
value was 0.51 for GHR, with a value of 0.64 for VEGF.
Individual SNP analyses showed the strongest association
for a variant allele in the 59 UTR of VEGF (rs25648, RefSNP
accession number assigned by dbSNP, http://www.ncbi.nlm.
nih.gov/projects/SNP). The MAF for this SNP among the
control population was 0.14, and the odds ratio (OR) (95%
conﬁdence interval [CI]) for heterozygote and homozygote
variant genotypes compared to the common homozygote
genotype was 1.12 (0.91–1.37) and 5.11 (2.33–11.20), respec-
tively; p-values for LRT (2 df) ¼ 1 3 10
 5 and for trend test ¼
0.002 (Table 2). The observed frequency for the homozygote
variant genotype was lower than expected under Hardy-
Weinberg equilibrium in the control population (0.8%
observed versus 1.9% expected, p-value ¼ 0.002), while
genotype completion and concordance for this SNP were
measured at 100%. To explore the impact of the observed
departure on estimates of relative risk, we re-estimated ORs
(95% CIs) assuming Hardy-Weinberg equilibrium [4]. Esti-
mates for heterozygote and homozygote variant genotypes
assuming Hardy-Weinberg equilibrium were 1.23 (1.02–1.48)
p-value ¼ 0.03 and 2.20 (1.48–3.28) p-value ¼ 0.00009,
respectively.
We performed additional genotyping for 29 SNPs in VEGF
(including the three SNPs previously genotyped) in an effort
to dissect the locus to follow-up ﬁndings from our explor-
atory analysis described above. Two of these SNPs showed low
genotypic variation in this population (no variants were
observed for rs3024989, and three controls and no cases were
heterozygote for rs9367173). The concordance for the three
VEGF SNPs previously genotyped in the GoldenGate assay
(rs1005230, rs25648, and rs3025039) was 100%. Genotype
completion and concordance rates for all VEGF SNPs
exceeded 99%, and all but rs25648 (p ¼ 0.002) were in
Hardy-Weinberg equilibrium in controls. Analyses showed
signiﬁcant associations with three additional SNPs located in
the promoter region of VEGF (rs833052, rs1109324, and
rs1547651) and one SNP in intron 2 (rs3024994) (Table 2).
However, the association for the rs833052 promoter SNP was
only borderline signiﬁcant. Two of these SNPs (rs1109324 and
rs1547651) were in strong linkage disequilibrium (LD) with
the 59 UTR SNP (D9   0.94 and r
2   0.84). None of the other
SNPs showed signiﬁcant associations with bladder cancer risk
(see Tables 2, S3, and S4 for more details).
We evaluated interactions between the VEGF SNPs
signiﬁcantly associated with bladder cancer risk and other
determinants of risk (i.e., age, gender, smoking status, family
history of cancer in at least one ﬁrst-degree relative, and
NAT2 and GSTM1 genotypes). Analyses suggested stronger
associations for the two correlated SNPs in the VEGF
promoter (rs1109324 and rs1547651) among subjects with a
family history of cancer (p-value for heterogeneity ¼ 0.035
and 0.036, respectively; Table S5). We also observed a
Table 2. Association between Selected VEGF Polymorphisms with Bladder Cancer Risk among 1,086 Cases and 1,033 Controls in the
Spanish Bladder Cancer Study
SNP Genotypes Cases Controls OR 95% CI p-value p-trend
rs833052 CC 677 687 1.00 (Reference)
 15648A . C CA 209 189 1.13 0.89 1.43 0.31
AA 19 8 2.52 1.06 5.97 0.036 0.062
rs1109324
a GG 623 645 1.00 (Reference)
 9228G . T GT 243 221 1.12 0.90 1.41 0.30
TT 25 10 2.74 1.26 5.98 0.011 0.034
rs1547651
a AA 619 638 1.00 (Reference)
 8339A . T AT 251 231 1.12 0.90 1.40 0.31
TT 27 9 3.01 1.36 6.63 0.0064 0.027
rs833061
b TT 237 243 1.00 (Reference)
 1497C . T CT 434 432 1.08 0.85 1.36 0.54
CC 216 198 1.23 0.93 1.62 0.15 0.15
rs2010963 GG 388 387 1.00 (Reference)
Ex1 þ 405C . G CG 395 396 0.95 0.78 1.18 0.66
CC 98 93 1.01 0.72 1.40 0.96 0.86
rs25648
a CC 746 752 1.00 (Reference)
Ex1 73C . T( 5 9 UTR) CT 296 271 1.12 0.91 1.37 0.29
TT 43 8 5.11 2.33 11.20 0.000045 0.0016
rs3024994 CC 837 783 1.00 (Reference)
IVS2 þ 1378C . T CT 69 96 0.65 0.46 0.91 0.012
TT 0 2
rs3025039
c CC 852 787 1.00 (Reference)
236 bp 39 of STP C .T CT 217 385 0.87 0.70 1.08 0.21
TT 17 11 1.63 0.73 3.61 0.23 0.59
SNPs shown were selected on the basis of being significantly related to bladder cancer risk or having functional significance in previous studies. Please see Table S3 for findings on all SNPs
evaluated in the study.
Analyses for rs833052, rs1109324, rs1547651, rs833061, rs2010963, and rs3024994 are based on 926 cases and 900 controls included in the iPLEX assay.
aHighly correlated SNPs (r
2 . 0.90 for all pair-wise comparisons, except for rs1547651 and rs25648 with r
2 ¼ 0.84).
bThis SNP showed high correlations (r
2 . 0.95) with three other promoter SNPs not shown in this table (rs1005230, rs699947, and rs833067).
cThis SNP showed high correlations (r
2 . 0.90) with two other SNPs in intron 7 not shown in this table (rs3025030 and rs3025033).
doi:10.1371/journal.pgen.0030029.t002
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VEGF and Bladder Cancer Riskstronger association for the 59 UTR SNP (rs25648) among
subjects with the GSTM1 null genotype (p-value for hetero-
geneity¼0.031; Table S5). However, these ﬁndings need to be
interpreted with caution given the number of interactions
evaluated.
Haplotype analyses were based on 27 VEGF SNPs (of the 29
SNPs determined, two were excluded because of low
genotypic variation). Of the three large blocks deﬁned by
LD in our control population (Figure 1), we observed
signiﬁcant associations between haplotypes and risk for
bladder cancer in two LD blocks, including the promoter
and 59 UTR (global p ¼ 0.023 and 0.043 for blocks 1 and 2,
respectively; Figure 2). Consistent with individual SNP
analyses, the AT haplotype in block 1 carrying the variant
allele for rs833052 was associated with increased bladder
cancer risk; however, the CT haplotype was related to
decreased bladder cancer risk, which was not predicted by
individual SNP analyses. Both the individual SNP and
haplotype associations were only of borderline signiﬁcance
and thus could be due to chance.
Of the nine observed haplotypes in block 2, only one
(GAGCCGTGCTGGTCCCT) carried the variant in intron 2
(rs3024994) that was individually associated with reduced risk
(Figure 2). Consistent with SNP analyses, this haplotype was
also associated with a reduction in risk. Two other haplotypes
carried at least one variant for three correlated SNPs
individually associated with risk (rs1109324, rs1547651, and
rs25648). Both haplotypes were associated with increases in
risk, although the association for the haplotye carrying only
the rs25648 variant (GAGATGCGTCGGCCCCC) was not
signiﬁcant, possibly due to its low frequency in the
population (1.0% of controls) (Figure 2). Therefore, hap-
lotype analyses cannot help distinguish which of the three
correlated SNPs is most important in determining risk.
Discussion
An exploratory analysis of 1,433 SNPs in or near 386 genes
involved in cancer-related pathways using the GoldenGate
assay led to the identiﬁcation of novel associations for several
promising genes, the most notable ﬁnding, a 59 UTR SNP in
VEGF. Subsequent analyses that captured nearly all common
variants in this gene showed additional associations with
SNPs in the promoter and intron 2, providing further
Figure 1. Gene Map and LD Plot of VEGF Gene
Color scheme is based on D9 and logarithm of the odds of linkage (LOD) score values: white D9,1 and LOD , 2, blue D9¼1 and LOD , 2, shades of
pink/red: D9,1 and LOD   2, and bright red D9¼1 and LOD   2. Numbers in squares are D9 values (values of 1.0 are not shown). Block definition is
based on the Gabriel et al. method [34]. Two (rs3024989 and rs367173) of the 29 SNPs determined are not shown because of low variation in this
population. Red rectangles in the gene map represent exons.
doi:10.1371/journal.pgen.0030029.g001
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VEGF and Bladder Cancer Riskevidence for the importance of variation in regulatory
elements of VEGF and bladder cancer risk.
The association of common genetic variation in VEGF with
bladder cancer risk is biologically plausible for several
reasons: (1) VEGF has been identiﬁed as a critical factor in
angiogenesis required for tumor growth, (2) VEGF expression
in bladder tumors has been related to tumor progression [5],
and (3) in vitro studies have suggested that common
haplotypes in the 59 region of VEGF alter gene expression
[6]. A large block of LD that extended from the promoter to
intron 5 included the 59 UTR SNP (rs25648) that demon-
strated the strongest association with bladder cancer risk in
our initial screen. This SNP showed a departure from Hardy-
Weinberg equilibrium in controls (p-value¼0.002), which was
not observed for two correlated SNPs in the promoter region
(rs1109324 and rs1547651; r
2 . 0.80 between the 59 UTR and
promoter SNPs) also associated with risk. We did not observe
more deviations from Hardy-Weinberg equilibrium than
expected by chance in our control population, the deviation
for rs25648 was not observed in other Caucasian populations
[7] (http://snp500cancer.nci.nih.gov), and quality control
samples did not show evidence for genotype errors; therefore,
this departure is likely to have occurred by chance. The
observed magnitude of the association for rs25648 was larger
than for the two promoter SNPs; however, this difference was
less apparent after re-estimation of ORs assuming Hardy-
Weinberg equilibrium, suggesting that it might have occurred
by chance.
Carriers of the 59 UTR SNP (rs25648) have been found to
have increased VEGF mRNA levels in adenocarcinoma tissues
of patients with colorectal adenocarcinomas [6]. Although
there are no functional studies of the two promoter SNPs
associated with bladder cancer risk in our study population,
previous studies have shown that variant genotypes or
haplotypes falling in the same block of LD (rs699947,
rs1570360, rs833061, and rs2010963) were associated with
(1) higher induced gene expression from hypoxia in transient
transfection assays [8]; (2) higher VEGF production in
peripheral blood mononuclear cells [9,10]; (3) increased
promoter activity and responsiveness to phorbol esters in
Figure 2. Phylogenetic Trees for VEGF Haplotypes and Association with Bladder Cancer Risk among 926 Cases and 900 Controls with DNA in the iPLEX
Assay, Spanish Bladder Cancer Study
See Figure 1 for block definitions. Of the 29 VEGF SNPs determined, two had low genotypic variation in our population; therefore, haplotype analyses
were based on the remaining 27 SNPs. Polymorphic bases are in 59 to 39 order: Block 1(rs833052 and rs866236); Block 2 (rs1109324, rs1547651,
rs833060, rs699947, rs1005230, rs833061, rs1570360, rs2010963, rs25648, rs833067, rs3025042, rs833068, rs3024994, rs735286, rs3024998, rs3025000,
and rs3025006); and Block 3 (rs3025030, rs3025033, rs3025035, and rs3025036). Bolded rs numbers are for individual SNPs significantly associated with
bladder cancer risk.
Eleven cases and 13 controls with missing data on more than 15 of the 17 SNPs in Block 2 were excluded from haplotype analyses because their
inclusion resulted in lack of convergence. Nucleotide changes significantly associated with risk in the individual genotype analyses are shown in boxes.
The most common haplotye is the reference category. Haplotypes with the common variant for each individual SNP are CC for Block 1,
GAGCCGTGCTGGCCCCC for Block 2, and GACC for Block 3.
doi:10.1371/journal.pgen.0030029.g002
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VEGF and Bladder Cancer Riskbreast cancer cell lines [11]; and (4) tumor aggressiveness in
breast cancer patients [12]. Finally, the SNP in intron 2
(rs3024994) associated with reduced risk fell in the same block
of LD but showed low correlation with other SNPs, and there
are no published studies on its functional signiﬁcance.
Only one SNP in VEGF (rs699947) has been previously
evaluated in relation to bladder cancer risk in a small study of
153 bladder cancer patients and 153 controls in South Korea
[13]. Consistent with our results, this study found no
association between this SNP and bladder cancer risk. A
SNP in 39 of STP (rs3025039) has been associated with
decreased plasma levels of VEGF and decreased breast cancer
risk [14]; however, neither this nor other SNPs in LD were
associated with bladder cancer risk in our study.
We also observed promising associations with bladder
cancer risk for other genes involved in carcinogenesis
pathways. However, based on FDR calculations, taking into
account all genes evaluated in this report, the additional
associations were not robust and thus should be pursued in
additional study populations.
To the best of our knowledge, this is the ﬁrst large-scale
evaluation of candidate genes in bladder cancer using highly
multiplexed technologies. Our data demonstrate that these
technologies provide high quality data and that they can be
useful in identifying genetic susceptibly factors. In particular,
we provide reasonable evidence for an association between
common variants in the promoter and 59 UTR of VEGF and
bladder cancer risk. Further work is required to replicate the
ﬁndings in other populations and to identify the potential
causal variant by more detailed genetic mapping, including
sequencing and functional characterization of variants.
Materials and Methods
Study population. The study population has been previously
described [2]. Brieﬂy, cases were patients participating in the Spanish
Bladder Cancer Study diagnosed with histologically conﬁrmed
bladder carcinoma in 1998–2001, aged 21–80 y (mean [sd] ¼ 66 [10]
y), of which 87% were males. Controls were selected from patients
admitted to participating hospitals for diagnoses believed to be
unrelated to the exposures of interest, individually matched to the
cases by age at interview within 5-y categories, gender, ethnicity, and
region. Demographic and risk factor information was collected at the
hospitals using computer-assisted personal interviews. A total of
1,219 cases (84% of eligible cases) and 1,271 controls (88% of eligible
controls) agreed to participate in the study and were interviewed. Of
these, 1,188 (97%) cases and 1,173 (92%) controls provided a blood or
buccal cell sample for DNA extraction. Adequate amounts of DNA
for genotyping were available from 1,116 cases (including eight from
buccal cells) and 1,043 controls (including 36 from buccal cells).
Further exclusions were made to reduce heterogeneity (cases with
nontransitional histology and nonwhite subjects), or because of DNA
contamination or lack of information on smoking status. After
exclusions, the available samples for genotype analysis were 1,086
cases and 1,033 controls.
We obtained informed consent from potential participants in
accordance with the National Cancer Institute and local institutional
review boards.
Genotyping. A GoldenGate assay (Illumina, http://www.illumina.
com) was developed using SNPs in the SNP500Cancer project (http://
snp500cancer.nci.nih.gov) with previous re-sequence analysis and
plausible evidence that the gene is related to carcinogenic processes
[3]. SNP selection favored nonsynonymous SNPs, those previously
evaluated in relation to cancer risk, or those with evidence for
functional signiﬁcance. The GoldenGate assay was designed to
examine 1,536 SNPs based on an initial screen of 3,072 SNPs drawn
from the SNP500Cancer database (November 2004) and subsequently
analyzed in the unrelated HapMap Centre d’Etude du Polymor-
phisme Humain (CEPH) Utah samples. Of the 1,536 assays chosen for
this study, 103 were dropped from the analysis because of low MAF or
assay problems. Thus, we obtained data on 1,433 SNPs in or near 386
genes (Table S1). DNA samples from cases and controls were
randomly sorted, including 69 duplicated DNA samples for genotyp-
ing quality control.
Based on our primary analysis that showed the strongest
association of bladder cancer with an SNP in VEGF, we performed
a comprehensive evaluation of common variation in this gene. We
initially selected 31 SNPs spanning 20 kb 59 of the start of
transcription to 10 kb 39 of the end of exon 8 of the VEGF gene
using the following methods: (1) 15 tag SNPs were chosen based on
the aggressive tagging algorithm [15] (r
2   0.80, MAF   0.05) using
genotype data from the unrelated HapMap CEPH Utah individuals;
(2) 16 SNPs from the Single Nucleotide Polymorphism database were
added as ‘‘ﬁll-in’’ to ensure the inclusion of an SNP every 2–5 kb
across the region, particularly in the 59 region. iPLEX (Sequenom,
http://www.sequenom.com) assays were designed and optimized with
the SNP500Cancer set of 102 individuals. Two SNPs were dropped
because of design and performance problems. Out of 29, 28 assays
were optimized on iPLEX and one SNP (rs699947) that could not be
included was analyzed using TaqMan (Applied Biosystems, http://
www.appliedbiosystems.com). Because of restricted amounts of DNA
available and poor assay performance for a small subset of samples
and exclusions for data analyses described earlier (cases with
nontransitional histology, nonwhite subjects, and lack of information
on smoking status), a total of 926 cases and 900 controls were
included in the analyses.
Statistical analysis. For each individual SNP, we estimated OR and
95% CI using logistic regression models adjusting for gender, age at
interview in 5-y categories, region, and smoking status (never,
occasional, former, and current; see [2] for details on the deﬁnition
of these variables). The association between individual SNPs and
bladder cancer risk was tested using a 2-df LRT and a linear trend test
assuming a dose response with increasing number of variant alleles.
ORs and 95% CIs ‘‘per variant allele’’ were estimated under the latter
assumption (i.e., coding genotypes as 0, 1, and 2 depending on the
number of variant alleles). Heterogeneity of genotype ORs among
groups of subjects deﬁned by age, gender, smoking status, family
history of cancer in at least one ﬁrst-degree relative, and NAT2 and
GSTM1 genotypes (see [2] for details on the deﬁnition of these
variables) were evaluated by introducing interaction terms in logistic
regression models.
The 1,433 individual SNPs evaluated were located within or near
386 candidate genes. We performed two gene-based tests for
association: (1) an LRT for each gene comparing models with and
without terms for heterozygous and homozygous variant genotypes
for each SNP in a given gene (df¼23number of SNPs per gene); (2)
an LRT for each gene comparing models with and without terms for
each SNP (genotypes coded as 0, 1, and 2) in a given gene (df ¼
number of SNPs per gene). For highly correlated SNPs (r
2 . 0.90)
within a gene, only one of the SNPs was included in the model to
avoid collinearity problems (Table S1).
Haplotype frequencies, ORs, and 95% CIs for genes showing blocks
of LD were estimated using HaploStats (http://mayoresearch.mayo.
edu/mayo/research/biostat/schaid.cfm). This program reconstructs
haplotypes and estimates ORs simultaneously based on a suitable
Expectation-Maximization algorithm [16,17].
We used the method described by J. Chen and N. Chatterjee to
obtain estimates and p-values for genotype associations assuming
Hardy-Weinberg equilibrium in the control population [4]. Phyloge-
netic trees (neighbor joining [18]) were constructed using MEGA 3.1
[19] (http://www.megasoftware.net) to assess nucleotide similarity of
different haplotypes.
We evaluated the robustness of our results using the FDR. FDR is
the expected ratio of erroneous rejections of the null hypothesis to
the total number of rejected hypothesis among all the genes or SNPs
analyzed in this report. Rather than using an arbitrary threshold FDR
value, we report the values for the most signiﬁcant associations to
allow the reader to evaluate the robustness of our ﬁndings. The
Benjamini and Hochberg method [20] was used to calculate FDR
values using ‘‘multtest’’ package in the R project for statistical
analyses (http://www.r-project.org). Unless otherwise speciﬁed, stat-
istical analyses were performed with STATA Version 8.2, Special
Edition (STATA Corporation, http://www.stata.com).
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Table S1. List of SNPs Included in the SNP500 Illumina GoldenGate
Assay, Spanish Bladder Cancer Study
Found at 10.1371/journal.pgen.0030029.st001 (1.2 MB DOC).
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Risk and SNPs with a p-value from a Trend Test or a 2-df LRT   0.01
in the Spanish Bladder Cancer Study
Found at 10.1371/journal.pgen.0030029.st002 (34 KB DOC).
Table S3. Association between Common Variants in VEGF and
Bladder Cancer Risk in the Spanish Bladder Cancer Study
Found at 10.1371/journal.pgen.0030029.st003 (233 KB DOC).
Table S4. Genotype Cell Counts for Cases and Controls
Found at 10.1371/journal.pgen.0030029.st004 (19 KB XLS).
Table S5. Modiﬁcation of the Association between Selected Variants
in VEGF and Bladder Cancer Risk by Age, Gender, Smoking Status,
Family History of Cancer, NAT2 and GSTM1 Genotypes
Found at 10.1371/journal.pgen.0030029.st005 (173 KB DOC).
Accession Numbers
The accession numbers for the Entrez Gene (http://www.ncbi.nlm.nih.
gov/entrez) genes discussed in this paper are ARHGDIB (397), CASP9
(842), CETP (1071), CYP1B1 (1545), CYP24A1 (1591), ESR1 (2099),
FZD7 (8324), GHR (2690), GPX4 (2879), GSTA4 (2941), HSD174 (3295),
LIPC (3990), PLA2G6 (8398), PTH (5741), RB1CC1 (9821), ROS1 (6098),
SHBG (6462), STAT1 (6772), STK11 (6794), TERT (7015), VEGF (7422),
XRCC4 (7518), and ZNF350 (59348).
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